KineMed Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:KineMed Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013233
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
KineMed Inc (KineMed) is a biotechnology company that develops and commercializes proprietary biomarker platform technology. The company applies its proprietary biomarker platform technology to drug development, prescription, and non-prescription medical diagnostics and the pairing of drugs with diagnostic biomarker tests. It utilizes isotope labeling, mass spectrometry, and other techniques to observe the activity of biochemical pathways, measure molecular fluxes within the pathways, and to monitor the appearance and disappearance of individual proteins and biological biomarkers. Kinmed develops drugs in the therapeutic areas of muscle metabolism, fibrosis, immunity, neurobiology, diabetes, cancer, and others. The company also conducts pharmaceutical research on molecular targets and deconstructed systems. KineMed is headquartered in Emeryville, California, the US.

KineMed Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
KineMed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
KineMed Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
KineMed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
KineMed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
KineMed Inc, Medical Devices Deals, 2011 to YTD 2017 9
KineMed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
KineMed Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
KineMed Raises Additional USD0.45 Million in Venture Financing 11
KineMed Raises USD1.69 Million in Venture Financing 12
KineMed Raises US$2 Million In Venture Financing 13
KineMed Raises US$1 Million In Venture Financing 14
Kinemed Secures Additional US$1.9 Million In Series F Financing 15
Partnerships 16
Neurotez Partners with KineMed 16
KineMed Enters into R&D Agreement with Pronutria Biosciences 17
KineMed Extends Research Agreement with Pfizer for Metabolic Disease Therapies 18
KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 19
KineMed Extends Research Agreement With Pfizer 20
KineMed Enters Into Co-Development Agreement With Pfizer 21
PsychoGenics Enters Into Joint Venture Agreement With KineMed 22
Licensing Agreements 23
Oxeia Biopharma Enters into Licensing Agreement with Kinemed 23
Pfizer Enters into Licensing Agreement with KineMed 24
KineMed Enters into Licensing Agreement with BioPharma Forest 25
KineMed Extends Licensing Agreement With Bristol-Myers Squibb 26
Equity Offering 27
KineMed Withdraws IPO 27
KineMed Inc – Key Competitors 29
KineMed Inc – Key Employees 30
KineMed Inc – Locations And Subsidiaries 31
Head Office 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
KineMed Inc, Pharmaceuticals & Healthcare, Key Facts 2
KineMed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
KineMed Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
KineMed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
KineMed Inc, Deals By Therapy Area, 2011 to YTD 2017 8
KineMed Inc, Medical Devices Deals, 2011 to YTD 2017 9
KineMed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
KineMed Raises Additional USD0.45 Million in Venture Financing 11
KineMed Raises USD1.69 Million in Venture Financing 12
KineMed Raises US$2 Million In Venture Financing 13
KineMed Raises US$1 Million In Venture Financing 14
Kinemed Secures Additional US$1.9 Million In Series F Financing 15
Neurotez Partners with KineMed 16
KineMed Enters into R&D Agreement with Pronutria Biosciences 17
KineMed Extends Research Agreement with Pfizer for Metabolic Disease Therapies 18
KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 19
KineMed Extends Research Agreement With Pfizer 20
KineMed Enters Into Co-Development Agreement With Pfizer 21
PsychoGenics Enters Into Joint Venture Agreement With KineMed 22
Oxeia Biopharma Enters into Licensing Agreement with Kinemed 23
Pfizer Enters into Licensing Agreement with KineMed 24
KineMed Enters into Licensing Agreement with BioPharma Forest 25
KineMed Extends Licensing Agreement With Bristol-Myers Squibb 26
KineMed Withdraws IPO 27
KineMed Inc, Key Competitors 29
KineMed Inc, Key Employees 30

★海外企業調査レポート[KineMed Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NARI Technology Development Co Ltd (600406):企業の財務・戦略的SWOT分析
    NARI Technology Development Co Ltd (600406) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Glow Energy Public Co Ltd (GLOW)-エネルギー分野:企業M&A・提携分析
    Summary Glow Energy Public Company Limited (Glow Energy), a subsidiary of Engie S.A., is an energy utility company. It generates and supplies electricity to Electricity Generating Authority of Thailand (EGAT). The company also generates and supplies electricity, steam, processed water and chilled wa …
  • PDF Solutions Inc (PDFS):企業の財務・戦略的SWOT分析
    Summary PDF Solutions Inc (PDF Solutions) is a technology company that offers yield improvement technologies and services for the IC manufacturing process life cycle. The company offers products such as Exensio Control, Exensio Yield, Exensio Test, Exensio Char, Yield Ramp Simulator and Circuit Surf …
  • Eurofins MWG Operon LLC-製薬・医療分野:企業M&A・提携分析
    Summary Eurofins MWG Operon LLC (Eurofins) is a biotechnology company that provides DNA sequencing, DNA synthesis and bioinformatic services. The company’s products include DNA tube oligos, large scale synthesis, large scale synthesis, oligo modifications, oligo modifications, real-time QPCR probes, …
  • Arab African International Bank:企業の戦略・SWOT・財務情報
    Arab African International Bank - Strategy, SWOT and Corporate Finance Report Summary Arab African International Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Fuji Heavy Industries, Ltd.:戦略・SWOT・企業財務分析
    Fuji Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Fuji Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Dover Corporation:企業の戦略・SWOT・財務情報
    Dover Corporation - Strategy, SWOT and Corporate Finance Report Summary Dover Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Neptune Technology Group Inc:企業の戦略的SWOT分析
    Neptune Technology Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Marubeni Corp (8002):石油・ガス:M&Aディール及び事業提携情報
    Summary Marubeni Corp (Marubeni) is an integrated trading and investment business that operates through its domestic and overseas subsidiaries. It provides various products and commodities such as agri and marine products, chemicals, energy, metals and minerals, machinery, textiles, forest products …
  • International Vaccine Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary International Vaccine Institute (IVI) is a non-profit organization that discovers, develops and delivers vaccines. The organization's vaccines include bivalent inactivated oral cholera vaccine, Vi-DT typhoid conjugate vaccine, bivalent typhoid conjugate vaccine, shigella vaccine, norovirus v …
  • Alibaba Group Holding Limited:戦略・SWOT・企業財務分析
    Alibaba Group Holding Limited - Strategy, SWOT and Corporate Finance Report Summary Alibaba Group Holding Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • GamaMabs Pharma SA:製薬・医療:M&Aディール及び事業提携情報
    Summary GamaMabs Pharma SA (GamaMabs) is a clinical-stage immuno-oncology company that develops optimized therapeutic antibodies for the treatment of cancer. The company’s lead product candidate GM102, is an anti-AMHR2, Emabling engineered humanized mAb product targeting the receptor of anti-Mulleri …
  • RWE AG:発電所・企業SWOT分析
    RWE AG - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives) …
  • Ingenico SA (ING):企業の財務・戦略的SWOT分析
    Ingenico SA (ING) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Hino Motors, Ltd.:企業の戦略・SWOT・財務分析
    Hino Motors, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hino Motors, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Domainex Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Domainex Ltd (Domainex) is a drug discovery service company that offers drug discovery programmes against a wide range of drug targets. The company provides services such as molecular biology / cdh, protein expression, assays, fragment screening, virtual screening, computational chemistry, m …
  • Covalon Technologies Ltd (COV)-医療機器分野:企業M&A・提携分析
    Summary Covalon Technologies Ltd (Covalon) is a researcher, developer and commercialization of medical devices and healthcare technologies. The company offers advanced wound solutions, infection prevention products and perioperative care products. Covalon offers wound care products such as collagen …
  • The Baltimore Life Insurance Co:企業の戦略・SWOT・財務分析
    The Baltimore Life Insurance Co - Strategy, SWOT and Corporate Finance Report Summary The Baltimore Life Insurance Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • NovoCure Ltd (NVCR):企業の財務・戦略的SWOT分析
    Summary NovoCure Ltd (NovoCure) is an drug company that offers development and commercialization of novel therapies for tumor treating fields. The company’s pipeline products find application in cancer indications such as malignant melanoma, hepatocellular carcinoma, ovarian cancer, breast cancer an …
  • Corium International Inc (CORI):企業の財務・戦略的SWOT分析
    Summary Corium International Inc (Corium) is a commercial-stage biopharmaceutical company that produces and develops central nervous system pharmaceutical products. The company develops transdermal healthcare products with the help of Corplex technology platform using small molecules. Its products i …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆